The Advantages of Restricted-Access Barrier Systems - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Advantages of Restricted-Access Barrier Systems
Filling machines often are installed in sterile rooms and separated by isolators to prevent contamination. These methods have certain drawbacks, including making interventions more difficult. Restricted-access barrier systems are an alternative that ensures sterility and facilitates interventions.


Pharmaceutical Technology




Patient safety often requires that drug products be filled and packaged in sterile conditions. Sterile cleanrooms and isolators prevent contamination during the filling process. The use of cleanrooms is well established, and isolators are gaining increased acceptance. Each method, however, has its drawbacks such as making process interventions more difficult. In certain applications, restricted-access barrier systems (RABS), which can provide a level of aseptic quality near that of isolators, offer an efficient alternative and more process flexibility.


Figure 1: Equipment in a cleanroom. Curtains mounted to the sterile air manifold or a safety partition separate the aseptic area from the cleanroom. The machine often will have its own filtration.
Sterile rooms. The aseptic processing of parenteral drugs and other sterile products such as opthalmic medicines and inhalers requires sterile handling to prevent the product from coming into contact with particulate and microbial impurities. For this reason, processing usually is performed in sterile rooms (see Figure 1).

Production equipment such as filling machines must have a hygienic design and must be sanitized regularly. In addition, operators cannot enter the sterile room until they change their clothing and are disinfected. Despite the precautions, experience with this methodology has shown that the major contamination source for the product continues to be the operators themselves. Incomplete disinfections, inappropriate operator actions, and problematic machinery that requires frequent manual interventions can cause viable contamination. Any biological contamination of a processing line and its associated drugs may pose a risk to patients receiving the product.

To prevent such risk, the production areas, production machinery, and processes must be validated for aseptic quality. For example, operators must work according to precise, certified standard operating procedures (SOPs), which require special training programs. In addition, the production technology must function reliably to minimize operator interventions. The sanitation procedures must ensure the maximum removal of microbial impurities. Complete sterilization (the removal of all divisible organisms) of the entire machine and the entire area is hard to achieve with open-cleanroom methodology (1).


Figure 2: Equipment in an isolator. Air is prepared and recirculated in the isolator through double-window systems or return-air ducts.
The pros and cons of isolator technology. Products with higher standards and greater security requirements necessitate the use of isolator technology, which completely encloses the aseptic working area (see Figure 2).

The high air-purity cleanroom (ISO class 5) inside an isolator is limited to the space above the machine's baseplate (2). The surrounding external area can have a lower air quality (a minimum of class 8) as long as the physical separation is maintained (3–5). This separation can be achieved using:

  • a separation wall between the aseptic area and the surrounding area (e.g., a plastic curtain [soft wall] or a metal partition with glass windows [hard wall]);
  • gloveports in the separation wall for manual interventions such as materials handling for microbiological monitoring or for responding to process disruptions;
  • sterile-transfer mechanisms for moving production components, tools, and monitoring material (double-door transfer systems are common);
  • mouseholes with format-specific parts to minimize the space around incoming and outgoing containers;
  • positive interior pressure relative to the surrounding room.


ADVERTISEMENT

RELATED CONTENT
The Role of Glasses in Aseptic Production: A Detail Often Ignored
Risk-Management Assessment of Visible-Residue Limits in Cleaning Validation
The Effect of Carrier Material on the Measured Resistance of Spores
The Importance of Pre-Use Integrity Testing in Sterilizing Filtration
Radiation Sterilization of Parenterals
blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
18%
To all process for new products only
13%
To select process for new products only
22%
To select processes for both new and legacy products
22%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here